Helixmith is committed to developing innovative medicines with plants that are safe for human use.
Such products have advantages over synthetic drugs for treatment of chronic and intractable diseases as they have better safety and multi-target mechanisms of action. Helixmith seeks to offer a new paradigm in conquering intractable diseases with limited current therapeutics by utilizing our advanced technologies and experiences.
Phytotherapeutics
Helixmith is dedicated in inventing and commercializing
plant-based pharmaceuticals and nutraceutical.
이메일무단수집거부
이메일주소 무단수집을 거부합니다.
본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나 그 밖의 기술적 장치를 이용하여 무단으로 수집되는 것을 거부하며, 이를 위반시 정보통신망법에 의해 형사 처벌됨을 유념하시기 바랍니다.
Indications and Mechanisms of Action
-
Osteoarthritis (PG201)
· Anti-Inflammation and Analgesic Activities
· Anti-Oxidation
· Cartilage Protection
-
Inflammatory Bowel Disease (HX204)
· Anti-Inflammation and Anti-Oxidation
· Improvement of Intestinal Microenvironment (tight junction, mucus secretion, etc.)
Development Status
Scroll
| Pipeline | Indication | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | approval and market launch | |
|---|---|---|---|---|---|---|---|
| Natural Product |
PG201 | Osteoarthritis |  LAYLA Tab. |
||||
| HX204 | Inflammatory bowel disease |
|
|||||